Clay Siegall is a founding father of Seattle Genetics, its President from June 2000 and its CEO from November 2002. The company was founded in 1998 had has had its operations around Human antibodies manipulation, study and eventually their packaging into drugs. Its connection ability with something else, e.g. therapy, provides their antibodies power just as Lego bricks do. An antibody destroys a cancer cell from the inside once it delivers a payload of toxic. This strategy could have Seattle Genetics catapulted into the community of Seattle’s biotech, a pharmaceutical company that it has long sought to anchor by overcoming the many ups and downs plaguing the sector.

Seattle Genetics has been ranked the largest Washington biotech with its market value approaching $10 billion and a list of 900 employees. It highly invests in marketing and research to achieve its ambition to be one of the companies that move to Pharma from biotech. Its flagship drug, Adcetris, treats a lymph system cancer that spreads from one organ to another. This cancer is referred to as Hodgkin lymphoma. The tests on the drug done in 2017 will have its tests take off if the results come out positive.

Clay Siegall said that the company was going global, oncology and multiproduct with proving from their long drugs list. He adds that all that he wants is to build a company that is great rather than selling their drugs to larger companies as is the case with other biotech firms. Information on global markets learned from the company’s partnership with Takeda has also made him have an office opened in Switzerland to allow for international marketing.

Clay Siegall’s experience of around 20years in development of therapeutic drug and cancer research has helped him in leading Seattle Genetics. He has led this company into a diverse field of cancer therapies based on antibodies including brentuximab vedotin or adcetri, that the United States FDA hurriedly approved in 2011. He has also led this company into capital-raising activities that have had it secure more than $670 million through private and public funding. Before Seattle Genetics co-founding, he worked with Bristol-Myers Squibb Research Institute of Pharmaceuticals in 1991 to 1997 and in the Health National Institute with the Cancer National Institute from 1988 to 1991. He also serves on Alder Biopharmaceuticals directors’ board as a member. He holds fifteen patents and has over 70 publications under his name. He got his Genetics PhD from Washington University and his Zoology B.S. from Maryland University.